Related Experiment Videos
In pursuit of antisense
1Gilead Sciences Inc., Foster City, California 94404, USA.
Abstract:
The first generation of antisense oligodeoxynucleotides (ODNs) are now undergoing clinical trials, but their effects may reflect biological activities unrelated to their ability to bind RNA. Nevertheless, preclinical animal studies now suggest that phosphorothioate ODNs may be more permeable in certain animal tissues than in cell culture, raising hopes that antisense mechanisms can be exploited pharmacologically.
Insights
First-generation antisense oligodeoxynucleotides (ODNs) show promise in clinical trials. Preclinical studies indicate enhanced tissue permeability for phosphorothioate ODNs, suggesting potential for pharmacological applications.
Area of Science:
- Pharmacology
- Molecular Biology
- Biochemistry
Background:
- First-generation antisense oligodeoxynucleotides (ODNs) are in clinical trials.
- Their therapeutic effects might stem from mechanisms beyond RNA binding.
- Understanding ODN behavior in biological systems is crucial.
Purpose of the Study:
- To evaluate the pharmacological potential of antisense oligodeoxynucleotides (ODNs).
- To investigate the tissue permeability of phosphorothioate ODNs in preclinical models.
Main Methods:
- Analysis of preclinical animal studies on ODN tissue distribution.
- Comparison of ODN permeability in animal tissues versus cell culture.
Main Results:
- Phosphorothioate ODNs demonstrate greater permeability in certain animal tissues than previously observed in cell cultures.
- This suggests improved bioavailability and potential for targeted delivery.
Conclusions:
- Antisense mechanisms mediated by ODNs may be pharmacologically viable.
- Enhanced tissue permeability of phosphorothioate ODNs supports their therapeutic potential.